R
Roche Glycart
Provider of in vitro diagnostics and provide transformative solutions for key therapeutic areas
About Roche Glycart
Roche Glycart AG operates as a center of excellence for cancer immunotherapy research and antibody engineering within the Roche Group. The company originated as GlycArt Biotechnology AG, a spin-off from the Swiss Federal Institute of Technology (ETH) in Zurich, founded in September 2000. Key founders include Dr. Pablo Umaña and Joël Jean-Mairet. Dr. Umaña's doctoral research at Caltech and ETH Zurich on the glycoengineering of antibodies formed the scientific basis for the company's core technology.
In July 2005, Roche acquired GlycArt Biotechnology for approximately 235 million Swiss francs, integrating it into its Pharma Research and Early Development (pRED) division. This acquisition was a strategic move for Roche to secure GlycArt's proprietary GlycoMAb® technology and its pipeline of preclinical antibody candidates for oncology. Post-acquisition, the entity became the Roche Innovation Center Zurich, focusing on developing new cancer medicines. The business is centered on research and development, specifically creating new potent antibody-based products to treat cancer.
The company's core offering is its GlycoMAb® technology platform, which modifies the carbohydrate component of therapeutic antibodies to boost their natural cell-killing mechanism, known as antibody-dependent cellular cytotoxicity (ADCC). This glycoengineering process enhances the potency of antibodies, making them more effective at destroying targeted cancer cells. The technology is applicable to various antibody types and can be implemented in standard production cell lines without disrupting productivity. A significant achievement stemming from this technology is the drug Gazyva (obinutuzumab), which in 2013 became the first medicine approved by the FDA under its Breakthrough Therapy designation for treating chronic lymphocytic leukemia. Since the acquisition, the team has grown from 29 to over 180 employees, all based in Schlieren, Switzerland.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jul 2005 | $0 | — | Undisclosed | — |
| SERIES A✓Equity / VC | Nov 2003 | $14M | $54M | Novartis Venture Fund | — |
Growth signals
Latest recorded traffic for Roche Glycart is 25K monthly website visits, down 21.9% over the last three months. Roche Glycart's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Roche Glycart in the Zurich ecosystem
The Roche Glycart office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Novartis Venture Fund
Other known investors7 additional known investors
ETH Zurich
BioMedVC
Deutsche Venture Capital
Forbion Capital Partners
Gilde Healthcare- GVGlobal Life Science Ventures
Quest Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Roche Glycart on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Roche Glycart’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










